A detailed history of Northern Trust Corp transactions in Humacyte, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 808,486 shares of HUMA stock, worth $3.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
808,486
Previous 572,462 41.23%
Holding current value
$3.91 Million
Previous $2.75 Million 60.1%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.11 - $9.46 $1.21 Million - $2.23 Million
236,024 Added 41.23%
808,486 $4.4 Million
Q2 2024

Aug 14, 2024

BUY
$2.87 - $9.1 $65,197 - $206,724
22,717 Added 4.13%
572,462 $2.75 Million
Q1 2024

May 14, 2024

SELL
$2.57 - $4.84 $39,480 - $74,352
-15,362 Reduced 2.72%
549,745 $1.71 Million
Q4 2023

Feb 13, 2024

BUY
$1.99 - $3.12 $92,576 - $145,145
46,521 Added 8.97%
565,107 $1.6 Million
Q3 2023

Nov 13, 2023

BUY
$2.75 - $4.48 $51,089 - $83,229
18,578 Added 3.72%
518,586 $1.52 Million
Q2 2023

Aug 11, 2023

BUY
$2.86 - $4.97 $40,529 - $70,429
14,171 Added 2.92%
500,008 $1.43 Million
Q1 2023

May 15, 2023

SELL
$2.11 - $3.25 $50,777 - $78,211
-24,065 Reduced 4.72%
485,837 $1.5 Million
Q4 2022

Feb 13, 2023

BUY
$2.02 - $3.62 $554,005 - $992,821
274,260 Added 116.39%
509,902 $1.08 Million
Q3 2022

Nov 14, 2022

SELL
$1.22 - $5.14 $8,231 - $34,679
-6,747 Reduced 2.78%
235,642 $769,000
Q2 2022

Aug 12, 2022

BUY
$3.21 - $7.86 $386,163 - $945,558
120,300 Added 98.53%
242,389 $777,000
Q1 2022

May 13, 2022

SELL
$4.65 - $7.4 $10,634 - $16,923
-2,287 Reduced 1.84%
122,089 $862,000
Q4 2021

Feb 08, 2022

BUY
$7.25 - $11.6 $901,726 - $1.44 Million
124,376 New
124,376 $901,000

Others Institutions Holding HUMA

About Humacyte, Inc.


  • Ticker HUMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,007,000
  • Market Cap $499M
  • Description
  • Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...
More about HUMA
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.